Open Orphan PLC Rule 2.9 Announcement (2648W)
December 10 2019 - 2:01AM
UK Regulatory
TIDMORPH
RNS Number : 2648W
Open Orphan PLC
10 December 2019
Open Orphan plc
("Open Orphan or the "Company")
Rule 2.9 Announcement
In accordance with Rule 2.9 of the City Code on takeovers and
Mergers, the Company confirms that, as at the close of business on
9 December 2019, being the last business day prior to the date of
this announcement, it had 254,572,567 ordinary shares of 0.1 pence
each in issue. The Company holds no ordinary shares in treasury.
Accordingly, the total number of voting rights in Open Orphan is
254,572,567. The International Securities Identification Number
("ISIN") for Open Orphan's ordinary shares is GB00B9275X97.
For further information please contact:
Open Orphan plc +353 (0)1 644 0007
Cathal Friel, Chief Executive Officer
Arden Partners plc (Nominated Adviser and Joint Broker) +44 (0)20 7614 5900
John Llewellyn-Lloyd / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) +353 (0)1 679 6363
Anthony Farrell
Camarco (Financial PR) +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focussed, rare and orphan drug
consulting services platform. The Company consists of four
elements: a European clinical research organisation and
consultancy; an orphan drug services business; a Virtual Rep and
Data Access Platform consisting of physicians and key opinion
leaders; and a Health Data Platform to partner with Patient
Advocacy Groups. The Company is targeting rapid growth in one of
the fastest growing sectors in the global pharmaceutical industry
targeting under-supplied treatment for life threatening or very
serious diseases and rare disorders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RTTBLBDDGUGBGCC
(END) Dow Jones Newswires
December 10, 2019 02:01 ET (07:01 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024